Post highlights CorMedix (CRMD) as a potential high-growth opportunity similar to Moderna's recent performance, projecting 1x-2x returns. Key risks include biotech volatility, clinical trial outcomes, regulatory approval uncertainty, and the speculative nature of comparing to past winners.

Post highlights CorMedix (CRMD) as a potential growth opportunity similar to Moderna's past performance, suggesting a 1-2x upside setup. Key risks include biotech volatility, clinical trial outcomes, regulatory approval uncertainty, and the speculative nature of comparing to past outlier performers.

Post compares PRME's cure capabilities favorably to MRNA, though lacks detailed supporting evidence or clinical data. Key risks include unsubstantiated claims, biotech volatility, and clinical trial uncertainties.

PHIO is trading at $1 with early-stage Phase 1 cancer immunotherapy showing complete tumor responses, positioned as a potential acquisition target following Moderna's Phase 3 success and massive valuation spike. Key risks include typical biotech hazards: Phase 1 data rarely translates to later stages, tiny sample sizes, high failure probability, and extreme speculative nature of pre-Phase 2 plays.

Moderna's mRNA cancer vaccine breakthrough (melanoma trial success with KEYTRUDA) is driving interest in personalized cancer treatments, creating a downstream investment opportunity in genetic sequencing companies that will be needed to identify tumor genetic targets for each patient receiving these personalized vaccines. Key risks include clinical trial setbacks, regulatory delays, and whether genetic sequencing demand will materialize as expected.

Biohaven (BHVN) is positioned as a potential high-growth biotech play similar to Moderna's trajectory, with pipeline candidates and development potential. Key risks include clinical trial failures, regulatory setbacks, competitive pressure from larger pharma, and typical biotech execution risk.

User is going full portfolio margin on the 2x leveraged Moderna ETF, betting on significant upside movement in MRNA stock. Key risks include leverage amplifying losses on downward moves, volatility decay in leveraged ETFs, and margin call risk.